Skip to main content
. 2022 Oct 7;13(2):2128048. doi: 10.1080/20008066.2022.2128048

Table 2.

Changes in symptoms and functioning from pre-treatment to three-month follow-up.

  M (SD) F P d µp2
  Pre Start Post 3-m f-u A B C
PSS-I 31.40 (8.21) 18.55 (10.06) 15.90 (11.88) 44.13 <.001 1.52 0.61 0.63 0.60
PCL-5 49.79 (11.23) 50.69 (11.44) 34.21 (14.84) 30.00 (16.93) 30.32 <.001 1.38 0.52 0.53 0.54
BDI-II 29.66 (10.35) 28.21 (12.17) 19.66 (10.57) 18.93 (13.83) 13.69 <.001 0.88 0.33 0.35 0.33
BAI 26.55 (12.33) 26.07 (13.44) 16.66 (12.33) 17.07 (13.48) 21.48 <.001 0.73 0.43 0.42 0.44
WSAS 21.52 (8.26) 21.72 (8.18) 19.41 (7.60) 18.66 (9.73) 2.37 .100 0.32 0.08 0.11 0.09
WHO-5 33.24 (17.17) 28.69 (18.36) 39.45 (19.38) 44.14 (20.77) 5.91 .003 −0.57 0.17 0.29 0.18
IIP-64 1.74 (0.50) 1.74 (0.49) 1.45 (0.47) 1.39 (0.57) 14.06 <.001 0.65 0.33 0.38 0.33

Note: Effect sizes (µp2) are reported according to the imputation method used: A = imputation using last observation carried forward/backward; B = raw data (no imputation); C = expectation maximization method. F and p values are calculated using method A. PSS-I = PTSD Symptom Scale – Interview for DSM-IV, PCL-5 = PTSD Checklist for DSM-5, BDI-II = Beck Depression Inventory, BAI = Beck Anxiety Inventory, WSAS = Work and Social Adjustment Scale, WHO-5 = The World Health Organisation – Five Well-Being Index, IIP-64 = Inventory of Interpersonal Problems.